Applied Molecular Transport, Inc. announced positive top-line Phase II results from the FILLMORE monotherapy trial for AMT-101 in patients with chronic pouchitis, an orphan indication with significant unmet medical need and no current FDA-approved therapies.
[Applied Molecular Transport, Inc.]